Publications by authors named "Agnese Vannini"
Globally, more than 1 million new cases of gastric cancer were estimated in 2020, ranking fourth in cancer mortality. Currently although in resectable gastric cancer and esophagogastric junction (EGJ) adenocarcinoma a perioperative triplet chemotherapy regimen including a fluoropyrimidine, a platinum compound and docetaxel (FLOT) demonstrated a better overall survival, the survival rate is still very low, and a massive effort is still required to improve clinical prognosis. High microsatellite instability (MSI-H) status in gastric cancer is a favorable prognostic factor but poor data are available on its predictive role for perioperative FLOT chemotherapy in resectable gastric cancer.
View Article and Find Full Text PDFArticle Synopsis
- Management of metastatic colorectal cancer (mCRC) involves a continuum of care, primarily utilizing options like trifluridine/tipiracil and regorafenib after patients progress on standard therapies.
- Fruquintinib, a selective inhibitor for VEGFR-1, -2, and -3, has shown significant anti-tumor effects and was approved for treatment in China based on the successful phase III FRESCO trial.
- The subsequent FRESCO-2 trial validated these findings in various regions, showing fruquintinib improves overall survival in a heavily pretreated population and highlighting the need for identifying patients who may benefit most from this therapy.
Resectable gastric or gastroesophageal (G/GEJ) cancer is a heterogeneous disease with no defined molecularly based treatment strategy. Unfortunately, nearly half of patients experience disease recurrence despite standard treatments (neoadjuvant and/or adjuvant chemotherapy/chemoradiotherapy and surgery). In this review, we summarize the evidence of potential tailored approaches in perioperative treatment of G/GEJ cancer, with a special focus on patients with human epidermal growth factor receptor-2(HER2)-positive and microsatellite instability-high (MSI-H) tumors.
View Article and Find Full Text PDFArticle Synopsis
- About half of metastatic colorectal cancers have RAS mutations, which are important for understanding prognosis and developing targeted therapies, particularly focusing on KRAS hotspot mutations.
- A study examined the association of KRAS mutations with patient characteristics, prognosis, and response to antiangiogenic treatments using data from 183 patients with advanced CRC.
- Results showed specific KRAS mutations linked to certain metastatic patterns and demographics, with KRAS exon 4 mutations associated with significantly longer overall survival compared to other mutations.
Background: Although the efficacy of molecularly target agents in vitro, their use in routine setting is limited mainly to the use of anti-HER2 and antiEGFR agents in vivo. Moreover, core biopsy of a single cancer site may not be representative of the whole expanding clones and cancer molecular profile at relapse may differ with respect to the primary tumor.
Methods: We assessed the status of a large panel of cancer driver genes by cell-free DNA (cfDNA) analysis in a cohort of 68 patients with 13 different solid tumors at disease progression.
Over the years, thanks to the addition of new generation systemic agents, as well as the use of more advanced and precise radiotherapy techniques, it was able to obtain a high curability rate for breast cancer. Anthracyclines play a key role in the treatment of breast disease, with a well-known benefit on disease-free survival of patients with positive nodal status. Trastuzumab have shown a significant outcome advantage after 1-year administration in case of HER2-positive disease.
View Article and Find Full Text PDFBoth endocrine and chemotherapy can be utilized for breast cancer patients' management, in multiple setting (i.e., primary systemic therapy, adjuvant, metastatic treatment).
View Article and Find Full Text PDFGallbladder neuroendocrine neoplasms (GB-NENs) are rare. The majority of GB-NENs are poorly differentiated, with increased mitotic activity and clinically aggressive course. Surgery is the only curative approach and the optimal medical treatment is uncertain.
View Article and Find Full Text PDFObjectives: Sunitinib is the standard care for first-line treatment of metastatic renal cell carcinoma. The aim of this study was to determine whether a sunitinib regimen of 50 mg/day 2-weeks on/1-week off could maintain the same dose-intensity as the standard 4-weeks on/2-weeks off schedule, and provide the same efficacy in terms of objective response, progression-free survival and overall survival, while reducing drug-related toxicity.
Methods: A total of 31 patients with metastatic renal cell carcinoma received sunitinib orally at the dose of 50 mg/day in a 2-weeks on/1-week off regimen until disease progression or intolerable toxicities occurred.